RadNet影像中心
估值 各估值倍数与自身5年区间的对比
同业对比 Diagnostics & Research
| 公司 | 市值 | 市盈率(TTM)i | 市净率i | 股息率i |
|---|---|---|---|---|
| RadNet影像中心 (RDNT) | 5.41B | -264.62 | 4.94 | 0.00% |
| Thermo Fisher Scientific (TMO) | 255.13B | 37.14 | 4.84 | 0.26% |
| Danaher (DHR) | 161.01B | 40.68 | 3.06 | 0.63% |
| Natera (NTRA) | 56.71B | -291.44 | 31.13 | 0.00% |
| Agilent Technologies (A) | 48.77B | 34.12 | 6.62 | 0.59% |
| IDEXX Laboratories Inc (IDXX) | 44.15B | 39.38 | 27.38 | 0.00% |
StockVane 追踪范围内同行业的其他公司。
Morningstar
当前股价低于晨星合理价值估算16.3%。
合理价值
RadNet Inc is assigned a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 12% discount to our quantitative fair value estimate of $80.04 per share; however, caution is warranted due to this estimate's high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.
The firm's balance sheet bolsters our quantitative valuation. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. Reflecting the firm's leverage is its EBITDA/interest coverage ratio of 4.7, which sits in the bottom 30% compared with peers globally. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. We believe this is a sign that shares could be undervalued.
Conversely, the firm's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 0.9%, a core component of profitability, ranks in the bottom 40% compared with global peers. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.
经济护城河
The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.
作者:Quantitative Equity Report
报价时间 2026-10-16 19:30:05 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
RadNet影像中心 讨论区 0 条评论